GenPat77 Pharmacogenetics

GenPat77 Pharmacogenetics AG was a Berlin-based biopharmaceutical company focused on developing innovative therapeutic agents for inflammatory immune diseases and autoimmune disorders. The company's research centered on the TIRC7 (T-cell immune response cDNA 7) pathway, a negative regulator of T and B cell activation. GenPat77 utilized its proprietary platform to develop monoclonal and bispecific antibodies aimed at treating conditions such as rheumatoid arthritis and organ transplant rejection. Despite securing significant venture capital and establishing partnerships with companies like Medarex, the company entered insolvency proceedings in late 2007 and was liquidated in 2008.